Share This Page
Drug Price Trends for NDC 00641-6056
✉ Email this page to a colleague
Average Pharmacy Cost for 00641-6056
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00641-6056
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| MIDAZOLAM HCL 1MG/ML INJ | Hikma Pharmaceuticals USA Inc. | 00641-6056-10 | 10X10ML | 9.73 | 2021-08-15 - 2026-08-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00641-6056
Introduction
The drug associated with National Drug Code (NDC) 00641-6056 is [Insert Drug Name], a therapeutic agent used primarily for [indicate condition or indication, e.g., oncology, neurology, infectious disease, etc.]. As an essential component of healthcare treatment protocols and subject to regulatory dynamics, understanding its market landscape and pricing trajectory is vital for stakeholders, including pharmaceutical companies, healthcare providers, insurers, and investors. This analysis provides an in-depth evaluation of current market conditions, future price projections, and strategic insights.
Product Overview & Regulatory Status
NDC 00641-6056 corresponds to [Drug Name, dosage, formulation] manufactured by [Manufacturer]. The drug has obtained regulatory approval from the [FDA/EMA/other relevant authority] on [date], and is indicated for [indications]. Its patent status, exclusivity period, or biosimilar competition greatly influences market dynamics and pricing strategies.
Current Market Landscape
Demand and Market Penetration
The drug’s demand primarily stems from [describe the primary therapeutic area]. Market penetration levels are influenced by:
- Efficacy & safety profile: Demonstrating significant clinical benefits over existing therapies.
- Prescribing trends: Influenced by clinical guidelines, physician preferences, and insurance reimbursements.
- Patient access and coverage: Determined by formulary inclusion and affordability factors.
Recent data suggests that the global market for [indication] therapies is estimated at $X billion in 2023, with [Drug Name] accounting for approximately Y%. Adoption rates are expected to grow driven by rising disease prevalence and emerging clinical evidence.
Competitive Landscape
NDC 00641-6056 faces competition from:
- Branded alternatives: Other patent-protected drugs offering similar or superior efficacy.
- Biosimilars and generics: As patent exclusivity expires, price competition intensifies.
- Emerging therapies: New modalities, such as gene therapy, may impact the future relevance of this drug.
Market share distribution is primarily dictated by [differentiator, e.g., efficacy, safety, cost]. Concerns over side effects or limited indications could restrict uptake.
Pricing History & Current Pricing
The drug's pricing landscape exhibits:
- A list price of $X per unit or dose.
- Reimbursement metrics vary by region but tend to be [high/moderate/low] in [countries or regions].
- Discounts, rebates, and negotiated prices significantly influence actual transaction prices.
Sources such as Medicare Part B and private insurers indicate an average reimbursement rate of $Y, with patient co-pays varying depending on insurance plans.
Market Drivers and Barriers
Drivers
- Increased disease prevalence: The rise in [indication] cases fuels demand.
- Regulatory approvals: New indications or formulations expand market scope.
- Technological advances: Improved manufacturing or delivery methods can reduce costs and improve patient compliance.
- Price inflation: Driven by healthcare inflation trends and high-cost therapies.
Barriers
- Patent cliffs and biosimilar entry: Erode pricing power.
- Regulatory and reimbursement challenges: Can slow adoption.
- Therapeutic competition: Efficacy and safety profiles of competitors.
- Manufacturing complexities: Supply chain disruptions affecting availability and price.
Price Projection Analysis
Historical Price Trends
Over the past [period], the average wholesale price (AWP) has experienced a [increase/decrease/stability] at an annual rate of X%. Factors contributing include:
- Patent exclusivity prolongation or expiry.
- Market entry of biosimilars or generics.
- Pricing pressures from payers and healthcare policies.
Forecast Methodology
Using a combination of market trend analysis, regulatory landscape review, and competitive dynamics, projections are based on:
- Patent expiry dates: Anticipated biosimilar entry post-[date].
- Market demand growth: Projected CAGR of X% over next [years].
- Pricing elasticity estimates: Expected to decline by Y% with increased competition.
- Regulatory and payer policies: Potential for price regulation or reimbursement changes.
Projected Price Range (Next 3-5 Years)
| Year | Estimated Average Price per Dose (USD) | Key Assumptions / Notes |
|---|---|---|
| 2024 | $X1 - $X2 | Stable demand, patent protection remains in effect |
| 2025 | $X2 - $X3 | Patent expiry approaching, biosimilar approval expected |
| 2026 | $X3 - $X4 | Biosimilar market entry reducing prices by Y% |
| 2027 | $X4 - $X5 | Increased competition leading to further price adjustments |
Note: Prices assume continued therapeutic indication approval and no disruptive regulatory or market events.
Strategic Implications for Stakeholders
- Pharmaceutical companies should monitor patent status and biosimilar development pipelines to optimize pricing and market share strategies.
- Healthcare providers and payers should evaluate cost-effectiveness profiles to inform formulary decisions.
- Investors must consider patent exclusivity timelines and emerging competitors to assess future profitability.
Conclusion
The market for [Drug Name] under NDC 00641-6056 is shaped by patent protection, competitive entry, and evolving clinical evidence. Prices are expected to experience moderate inflation until patent expiry, after which biosimilar competition will substantially reduce costs. Stakeholders should anticipate dynamic regulatory and market conditions impacting both demand and pricing trajectories.
Key Takeaways
- The current market value of [Drug Name] is approximately $X with growth aligned with [indication] prevalence.
- Patent expiry within the next [duration] will introduce biosimilar competition, likely reducing prices by Y%.
- Market penetration is constrained by [list key factors, e.g., safety concerns, competition] but driven by increasing demand.
- Price projections indicate a [gradual decline/stability] post-patent expiry, emphasizing the importance of strategic patent management.
- Stakeholders must continuously monitor regulatory developments, biosimilar pipeline progress, and payer policies to optimize market positioning.
FAQs
-
What is the patent expiry date for NDC: 00641-6056?
Patent expiry is anticipated around [date], after which biosimilars are expected to enter the market. -
How does biosimilar competition influence pricing for this drug?
Biosimilar entry generally leads to significant price reductions—often by 50-70%—depending on market uptake and regulatory factors. -
Are there ongoing clinical trials that could impact the drug's market?
Yes, several trials are underway exploring new indications or formulations, which could expand or alter its market profile. -
What regional factors affect pricing?
Pricing varies globally due to differing healthcare policies, reimbursement systems, and market access regulations. -
How should investors interpret future price trends for this drug?
Post-patent expiry, expect considerable price erosion due to biosimilar competition; pre-expiry, focus on patent status and regulatory milestones.
References
[1] Industry reports on global pharmaceutical market trends.
[2] U.S. FDA database for regulatory approvals and patent information.
[3] Healthcare market analysis firms for demand and pricing data.
[4] Price trend data from IQVIA and Medicare reimbursement reports.
[5] Patent expiration timelines from patent databases like INPADOC or USPTO.
Note: Specific drug name, manufacturer, formulation, and precise financial figures must be customized upon verifying the latest authoritative sources.
More… ↓
